A detailed history of Morgan Stanley transactions in Beam Therapeutics Inc. stock. As of the latest transaction made, Morgan Stanley holds 4,123,575 shares of BEAM stock, worth $98.2 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
4,123,575
Previous 4,184,342 1.45%
Holding current value
$98.2 Million
Previous $114 Million 19.62%
% of portfolio
0.01%
Previous 0.01%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$23.46 - $45.07 $1.43 Million - $2.74 Million
-60,767 Reduced 1.45%
4,123,575 $136 Million
Q4 2023

Feb 13, 2024

BUY
$17.69 - $30.76 $64.8 Million - $113 Million
3,662,213 Added 701.4%
4,184,342 $114 Million
Q3 2023

Nov 15, 2023

SELL
$23.01 - $32.46 $7.2 Million - $10.2 Million
-313,063 Reduced 37.48%
522,129 $12.6 Million
Q2 2023

Aug 14, 2023

BUY
$29.32 - $35.99 $3.08 Million - $3.78 Million
105,064 Added 14.39%
835,192 $26.7 Million
Q1 2023

May 15, 2023

BUY
$30.15 - $48.79 $2.44 Million - $3.95 Million
81,024 Added 12.48%
730,128 $22.4 Million
Q4 2022

Feb 14, 2023

BUY
$36.73 - $51.6 $4.7 Million - $6.6 Million
127,984 Added 24.56%
649,104 $25.4 Million
Q3 2022

Nov 14, 2022

SELL
$39.79 - $70.31 $3.28 Million - $5.79 Million
-82,370 Reduced 13.65%
521,120 $24.8 Million
Q2 2022

Oct 27, 2022

BUY
$29.86 - $62.36 $1.55 Million - $3.24 Million
52,024 Added 9.43%
603,490 $23.4 Million
Q2 2022

Aug 15, 2022

BUY
$29.86 - $62.36 $1.55 Million - $3.24 Million
52,024 Added 9.43%
603,490 $23.4 Million
Q1 2022

Oct 27, 2022

SELL
$53.73 - $82.16 $2.8 Million - $4.27 Million
-52,024 Reduced 8.62%
551,466 $31.6 Million
Q1 2022

May 13, 2022

BUY
$53.73 - $82.16 $4.05 Million - $6.19 Million
75,378 Added 15.83%
551,466 $31.6 Million
Q4 2021

Feb 14, 2022

BUY
$68.02 - $99.06 $1.19 Million - $1.73 Million
17,464 Added 3.81%
476,088 $37.9 Million
Q3 2021

Nov 15, 2021

BUY
$84.37 - $133.6 $38.7 Million - $61.3 Million
458,624 New
458,624 $39.9 Million

Others Institutions Holding BEAM

About Beam Therapeutics Inc.


  • Ticker BEAM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 70,354,600
  • Market Cap $1.68B
  • Description
  • Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen ...
More about BEAM
Track This Portfolio

Track Morgan Stanley Portfolio

Follow Morgan Stanley and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.